In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
G BelvedereM D'Incalci

Abstract

In order to simulate drug resistance observed in the clinic, two cisplatin-resistant cell lines were produced from a murine ovarian reticulosarcoma, M5076 (M5), by pulse (M5/CDDP) and continuous (M5/CDDPc) treatment with cis-diamminedichloroplatinum(II)(CDDP). These cell lines showed a similar stable low level of resistance (approximately 3-fold) to CDDP and cross-resistance to carboplatin, iproplatin and the new alkylating agent tallimustine, but not to L-PAM (L-phenylalanine mustard) and BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea). Collateral sensitivity to two inhibitors of topoisomerase II, VP16 (etoposide) and doxorubicin (Dox), but cross-resistance to the topoisomerase I inhibitor, camptothecin, were observed. The two cell lines were also sensitive to 5-fluorouracil. No increase in the level of glutathione or activity of glutathione S-transferase could be observed in resistant cells compared with the parental M5 cells. Total DNA platination immediately after treatment was similar in the parental and resistant cell lines. Repair of total DNA platination, measured after 24 h of recovery, was undetectable in M5 and M5/CDDP cells, but was 33% in M5/ CDDPc cells. Initial DNA-interstrand cross-links (DNA-ISC) were six times hig...Continue Reading

References

Jan 1, 1978·Antibiotics and Chemotherapy·F M SchabelM H Witt
Feb 1, 1992·International Journal of Immunopharmacology·F RigantiA Vecchi
Dec 1, 1990·Cancer Treatment Reviews·C MeijerE G de Vries
Jun 15, 1989·International Journal of Cancer. Journal International Du Cancer·A FerrariM D'Incalci
Jun 15, 1987·International Journal of Cancer. Journal International Du Cancer·C R WolfJ F Smyth
Apr 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·E FreiW A Haseltine
May 15, 1985·Cancer·B Rosenberg
Jan 1, 1984·Journal of Cancer Research and Clinical Oncology·C J Rodenburg, F J Cleton
Sep 1, 1984·British Journal of Cancer·A P Simmonds, E C McDonald
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B T HillS A Shellard
Aug 1, 1993·In Vitro Cellular & Developmental Biology. Animal·G BalconiM D'Incalci
Dec 8, 2007·Clinical Journal of Oncology Nursing·Keith MarinPaula Muehlbauer

❮ Previous
Next ❯

Citations

Nov 12, 2005·Cancer Chemotherapy and Pharmacology·Britta K StordalRoss A Davey
Apr 13, 2007·Journal of Occupational Health·Jessica K Ljungberg, Gregory Neely

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.